GlaxoSmithKline (GSK) Announces Quarterly Earnings Results, Misses Expectations By $0.02 EPS

GlaxoSmithKline (NYSE:GSK) released its quarterly earnings results on Wednesday. The pharmaceutical company reported $0.68 EPS for the quarter, missing the consensus estimate of $0.70 by ($0.02), Morningstar.com reports. GlaxoSmithKline had a net margin of 4.97% and a return on equity of 130.63%. The business had revenue of $10.04 billion during the quarter, compared to analysts’ expectations of $10.26 billion.

NYSE:GSK opened at $39.12 on Thursday. The company has a debt-to-equity ratio of 4.09, a quick ratio of 0.39 and a current ratio of 0.60. GlaxoSmithKline has a fifty-two week low of $34.52 and a fifty-two week high of $44.53. The firm has a market cap of $100,764.20, a PE ratio of 13.58, a P/E/G ratio of 2.11 and a beta of 0.84.

How to Become a New Pot Stock Millionaire

The business also recently declared a quarterly dividend, which was paid on Thursday, April 12th. Stockholders of record on Friday, February 23rd were paid a dividend of $0.633 per share. The ex-dividend date of this dividend was Thursday, February 22nd. This is a boost from GlaxoSmithKline’s previous quarterly dividend of $0.50. This represents a $2.53 dividend on an annualized basis and a dividend yield of 6.47%. GlaxoSmithKline’s dividend payout ratio is 89.93%.

Several research firms recently commented on GSK. Zacks Investment Research downgraded shares of GlaxoSmithKline from a “buy” rating to a “hold” rating in a research report on Wednesday, January 10th. TheStreet cut shares of GlaxoSmithKline from a “b-” rating to a “c” rating in a research note on Wednesday, February 7th. Kepler Capital Markets raised shares of GlaxoSmithKline from a “reduce” rating to a “hold” rating in a research note on Friday, February 9th. JPMorgan Chase reissued a “neutral” rating on shares of GlaxoSmithKline in a research note on Monday, February 5th. Finally, Morgan Stanley raised shares of GlaxoSmithKline from an “underweight” rating to an “equal weight” rating in a research note on Thursday, March 22nd. One analyst has rated the stock with a sell rating, ten have issued a hold rating and five have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $40.21.

Several large investors have recently bought and sold shares of the company. Cambridge Investment Research Advisors Inc. grew its stake in shares of GlaxoSmithKline by 5.5% during the 4th quarter. Cambridge Investment Research Advisors Inc. now owns 107,873 shares of the pharmaceutical company’s stock worth $3,826,000 after purchasing an additional 5,582 shares during the period. OLD Republic International Corp grew its stake in shares of GlaxoSmithKline by 22.1% during the 4th quarter. OLD Republic International Corp now owns 1,538,500 shares of the pharmaceutical company’s stock worth $54,571,000 after purchasing an additional 278,000 shares during the period. Letko Brosseau & Associates Inc. grew its stake in shares of GlaxoSmithKline by 3.0% during the 4th quarter. Letko Brosseau & Associates Inc. now owns 1,027,688 shares of the pharmaceutical company’s stock worth $36,452,000 after purchasing an additional 30,000 shares during the period. Delek Group Ltd. acquired a new position in shares of GlaxoSmithKline during the 4th quarter worth $1,229,000. Finally, Sawtooth Solutions LLC grew its stake in shares of GlaxoSmithKline by 316.0% during the 4th quarter. Sawtooth Solutions LLC now owns 24,054 shares of the pharmaceutical company’s stock worth $853,000 after purchasing an additional 18,272 shares during the period. 10.96% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: This news story was first reported by Week Herald and is the property of of Week Herald. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this news story can be read at https://weekherald.com/2018/04/26/glaxosmithkline-gsk-announces-quarterly-earnings-results-misses-expectations-by-0-02-eps.html.

About GlaxoSmithKline

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Earnings History for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply